18F-FDG-PET/CT can be used to predict distant metastasis in hypopharyngeal squamous cell carcinoma
Tóm tắt
Hypopharyngeal squamous cell carcinoma (HPSCC) has a high rate of distant metastasis, resulting in poor prognosis. The role of the maximum standardized uptake value (SUVmax), which was assessed via pretreatment 18-fluorodeoxyglucose positron emission tomography (FDG-PET), and computed tomography (CT) was examined, for predicting distant metastasis and survival. This study included 121 patients who underwent pretreatment FDG-PET/CT scanning and subsequent treatment for HPSCC. The SUVmax was measured via FDG-PET/CT. A receiver operating characteristic (ROC) curve analysis was used to determine whether the SUVmax was a predictor of distant metastasis and to select the best cutoff value. Univariate and multivariate Cox hazard regression analyses were used in identifying associations between the SUVmax and other clinicopathological factors with distant metastasis-free survival. Distant metastases were identified in 33 patients during the median follow-up of 24 months after treatment. The ROC curve analysis determined that SUVmax was predictive of distant metastasis and identified a SUVmax of 13.9 as the best potential cutoff value. The univariate analysis showed that T and N classification, clinical stage, and SUVmax were significantly related to distant metastasis. However, in multivariate analysis, an SUVmax ≥ 13.9 was the only independent predictor of distant metastasis. Patients with high SUVmax values displayed significantly shorter distant metastasis-free survival and overall survival. SUVmax determined via pretreatment FDG-PET/CT is useful for predicting distant metastasis, distant metastasis-free survival, and overall survival in patients with HPSCC.
Tài liệu tham khảo
Newman JR, Connolly TM, Illing EA, Kilgore ML, Locher JL, Carroll WR. Survival trends in hypopharyngeal cancer: a population-based review. Laryngoscope. 2015;125:624–9. https://doi.org/10.1002/lary.24915.
Creff G, Devillers A, Depeursinge A, Palard-Novello X, Acosta O, Jegoux F, Castelli J. Evaluation of the prognostic value of FDG PET/CT parameters for patients with surgically treated head and neck cancer: a systematic review. JAMA Otolaryngol Head Neck Surg. 2020;146:471–9. https://doi.org/10.1001/jamaoto.2020.0014.
Li Y, Ou X, Hu C. Prevalence and prognostic impact of synchronous distant metastases in patients with hypopharynx squamous cell carcinomas: a SEER-based study. J Cancer. 2019;10:620–6. https://doi.org/10.7150/jca.28554.
Spector GJ. Distant metastases from laryngeal and hypopharyngeal cancer. ORL. 2001;63:224–8. https://doi.org/10.1159/000055746.
Castelli J, De Bari B, Depeursinge A, Simon A, Devillers A, Roman Jimenez G, Prior J, Ozsahin M, de Crevoisier R, Bourhis J. Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy. Crit Rev Oncol Hematol. 2016;108:40–51. https://doi.org/10.1016/j.critrevonc.2016.10.009.
Doi H, Kitajima K, Fukushima K, Kawanaka Y. SUV max on FDG-PET is a predictor of prognosis in patients with maxillary sinus cancer. Jpn J Radiol. 2016;34:349–55. https://doi.org/10.1007/s11604-016-0531-9.
Suzuki H, Kato K, Fujimoto Y, Itoh Y, Hiramatsu M, Maruo T, Naganawa S, Hasegawa Y, Nakashima T. 18F-FDG-PET/CT predicts survival in hypopharyngeal squamous cell carcinoma. Ann Nucl Med. 2013;27:297–302. https://doi.org/10.1007/s12149-013-0686-8.
Werner J, Hüllner MW, Rupp NJ, Huber AM, Broglie MA, Huber GF, Morand GB. Predictive value of pretherapeutic maximum standardized uptake value (Suvmax) in laryngeal and hypopharyngeal cancer. Sci Rep. 2019;9:1–10. https://doi.org/10.1038/s41598-019-45462-y.
Lee JR, Almuhaimid TM, Roh JL, Oh JS, Kim SJ, Kim JS, Choi SH, Nam SY, Kim SY. Prognostic value of 18F-FDG PET/CT parameters in patients who undergo salvage treatments for recurrent squamous cell carcinoma of the larynx and hypopharynx. J Surg Oncol. 2018;118:644–50. https://doi.org/10.1002/jso.25185.
Suzuki H, Kato K, Nishio M, Tamaki T, Fujimoto Y, Hiramatsu M, Hanai N, Kodaira T, Itoh Y, Naganawa S, et al. FDG-PET/CT predicts survival and lung metastasis of hypopharyngeal cancer in a multi-institutional retrospective study. Ann Nucl Med. 2017;31:514–20. https://doi.org/10.1007/s12149-017-1176-1.
Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, 8th edition | Wiley. Wiley-Blackwell (2017) Available at: https://www.wiley.com/en-us/TNM+Classification+of+Malignant+Tumours,+8th+Edition-p-9781119263579. Accessed January 12, 2022
Ishizuka M, Fujimoto Y, Itoh Y, Kitagawa K, Sano M, Miyagawa Y, Ando A, Hiramatsu M, Hirasawa N, Ishihara S, et al. Relationship between hematotoxicity and serum albumin level in the treatment of head and neck cancers with concurrent chemoradiotherapy using cisplatin. Jpn J Clin Oncol. 2011;41:973–9. https://doi.org/10.1093/jjco/hyr076.
Nakahara R, Kodaira T, Furutani K, Tachibana H, Tomita N, Inokuchi H, Mizoguchi N, Goto Y, Ito Y, Naganawa S. Treatment outcomes of definitive chemoradiotherapy for patients with hypopharyngeal cancer. J Radiat Res. 2012;53:906–15. https://doi.org/10.1093/jrr/rrs052.
Pisani P, Airoldi M, Allais A, Valletti PA, Battista M, Benazzo M, Briatore R, Cacciola S, Cocuzza S, Colombo A, et al. Metastatic disease in head and neck oncology. Acta Otorhinolaryngol Ital. 2020;40:S1–86. https://doi.org/10.14639/0392-100X-suppl.1-40-2020.
Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, Shedd DP. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg. 1987;154:439–42. https://doi.org/10.1016/0002-9610(89)90020-2.
Duprez F, Berwouts D, De Neve W, Bonte K, Boterberg T, Deron P, Huvenne W, Rottey S, Mareel M. Distant metastases in head and neck cancer. Head Neck. 2017;39:1733–43. https://doi.org/10.1002/hed.24687.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H-R, Cupissol D, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27. https://doi.org/10.1056/NEJMoa0802656.
Wiegand S. Survival after distant metastasis in head and neck cancer. Head Neck. 2016;38:140–6. https://doi.org/10.1002/hed.23861.
Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67. https://doi.org/10.1056/NEJMoa1602252.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7.
Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393–410. https://doi.org/10.1038/nrc3064.
Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352:175–80. https://doi.org/10.1126/science.aaf4405.
Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, Kim EE, Lee DS. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med. 2014;55:884–90. https://doi.org/10.2967/jnumed.113.133801.
Park GC, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol. 2013;24:208–14. https://doi.org/10.1093/annonc/mds247.
Krak NC, Boellaard R, Hoekstra OS, Twisk JWR, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32:294–301. https://doi.org/10.1007/s00259-004-1566-1.
Paidpally V, Chirindel A, Lam S, Agrawal N, Quon H, Subramaniam RM. FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med. 2012;4:633–47. https://doi.org/10.2217/iim.12.60.